SillaJen Inc Cash Flow Conversion Efficiency
SillaJen Inc cash flow conversion efficiency. Based on the latest financial reports, SillaJen Inc (215600) has a cash flow conversion efficiency ratio of -0.040x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.74 Billion ≈ $-3.21 Million USD) by net assets (₩117.80 Billion ≈ $79.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SillaJen Inc (2015–2024)
Cash flow conversion efficiency of SillaJen Inc from 2015 to 2024. This chart illustrates how SillaJen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 215600 share price today for real-time trading data and today's change.
SillaJen Inc Cash Flow Conversion Ratio Explained
SillaJen Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SillaJen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SillaJen Inc ranked by their cash flow conversion efficiency. Also see SillaJen Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sunjuice Holdings Co Ltd
TW:1256
|
0.020x |
|
Bicycle Therapeutics Ltd
NASDAQ:BCYC
|
-0.097x |
|
Bicycle Therapeutics plc
F:50BA
|
-0.097x |
|
Goodluck India Limited
NSE:GOODLUCK
|
0.037x |
|
Iones Co. Ltd
KQ:114810
|
-0.011x |
|
IG Petrochemicals Limited
NSE:IGPL
|
-0.029x |
|
Kangda International Environmental Company Limited
STU:27K
|
0.001x |
|
Ador Welding Limited
NSE:ADORWELD
|
0.013x |
Annual Cash Flow Conversion Efficiency for SillaJen Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of SillaJen Inc from 2015 to 2024. Review SillaJen Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩131.82 Billion ≈ $89.33 Million |
₩-17.83 Billion ≈ $-12.08 Million |
-0.135x | +54.44% |
| 2023-12-31 | ₩57.31 Billion ≈ $38.84 Million |
₩-17.02 Billion ≈ $-11.53 Million |
-0.297x | -5.86% |
| 2022-12-31 | ₩78.94 Billion ≈ $53.50 Million |
₩-22.14 Billion ≈ $-15.00 Million |
-0.280x | +50.07% |
| 2021-12-31 | ₩108.05 Billion ≈ $73.22 Million |
₩-60.69 Billion ≈ $-41.13 Million |
-0.562x | +43.98% |
| 2020-12-31 | ₩22.88 Billion ≈ $15.51 Million |
₩-22.94 Billion ≈ $-15.55 Million |
-1.003x | -241.83% |
| 2018-12-31 | ₩165.09 Billion ≈ $111.88 Million |
₩-48.43 Billion ≈ $-32.82 Million |
-0.293x | -275.11% |
| 2017-12-31 | ₩201.95 Billion ≈ $136.86 Million |
₩33.83 Billion ≈ $22.93 Million |
0.168x | +117.60% |
| 2016-12-31 | ₩207.97 Billion ≈ $140.94 Million |
₩-197.98 Billion ≈ $-134.17 Million |
-0.952x | -269.66% |
| 2015-12-31 | ₩86.94 Billion ≈ $58.91 Million |
₩-22.39 Billion ≈ $-15.17 Million |
-0.258x | -- |
About SillaJen Inc
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more